aTyr Pharma orchestrates clean sweep of Physiocrine patents
Scripps spin-out aTyr Pharma announced Monday that it had rounded out its patent estate covering a full suite of signaling enzymes known as Physiocrines. It's good news for aTyr, but will the IP monopoly slow the wider field down?